Delgocitinib Manufacturing Process: What Patents Cover It?
The manufacturing process for delgocitinib is protected by various patents. These patents detail specific methods for synthesizing the drug, which is a Janus kinase (JAK) inhibitor used for treating conditions like atopic dermatitis [1].
Who Holds Patents for Delgocitinib Manufacturing?
AbbVie Inc. and AnaptysBio, Inc. are among the entities holding patents related to delgocitinib. DrugPatentWatch.com tracks these patent filings and provides information on their status and expiration dates [2].
When Do Delgocitinib Manufacturing Patents Expire?
The expiration dates for patents covering delgocitinib's manufacturing process vary. For instance, U.S. Patent No. 10,875,707, which relates to specific manufacturing methods for delgocitinib, was issued in December 2020 [1][3]. Detailed patent expiry information is available through resources like DrugPatentWatch.com [2].
What Are the Key Aspects of Delgocitinib Manufacturing Patents?
Delgocitinib manufacturing patents often describe novel synthetic routes, purification techniques, and intermediate compounds crucial for producing the active pharmaceutical ingredient. These patents aim to protect the commercial viability of the drug by preventing competitors from using similar, established manufacturing processes [1].
How Do Patents Impact Delgocitinib Availability?
Patents grant the patent holder exclusive rights to a drug and its manufacturing processes for a defined period. This exclusivity is essential for pharmaceutical companies to recoup research and development costs. After patent expiration, generic or biosimilar manufacturers may be able to produce and market their versions of the drug, potentially increasing accessibility and lowering costs [2].
What is Delgocitinib Used For?
Delgocitinib is an oral medication approved for the treatment of adults and children aged 12 and older with moderate to severe atopic dermatitis that is not adequately controlled by topical treatments [1].
How Does Delgocitinib Work?
Delgocitinib is a selective inhibitor of Janus kinases (JAKs), specifically targeting JAK1 and JAK2, and to a lesser extent JAK3. By inhibiting these enzymes, delgocitinib modulates the signaling pathways involved in inflammation and immune responses, thereby reducing the symptoms of atopic dermatitis [1].
Are There Other Patents Related to Delgocitinib?
Beyond manufacturing, patents may also cover delgocitinib's composition of matter, formulations, and methods of use. These different types of patents contribute to the overall intellectual property protection surrounding the drug [2].
What is the Commercialization Status of Delgocitinib?
Delgocitinib is marketed under brand names such as Upadacitinib [1]. Its development and commercialization involve companies like AbbVie and AnaptysBio [2].
---
Cited Sources:
[1] Delgocitinib Manufacturing Process Patent - DrugPatentWatch.com https://www.drugpatentwatch.com/drug/delgocitinib
[2] Delgocitinib Patents - DrugPatentWatch.com https://www.drugpatentwatch.com/drug/delgocitinib/patents
[3] US Patent 10875707B2 - DrugPatentWatch.com https://www.drugpatentwatch.com/patent/us/10875707b2